128 related articles for article (PubMed ID: 25154504)
1. Gadolinium detection via in vivo prompt gamma neutron activation analysis following gadolinium-based contrast agent injection: a pilot study in 10 human participants.
Gräfe JL; McNeill FE; Noseworthy MD; Chettle DR
Physiol Meas; 2014 Sep; 35(9):1861-72. PubMed ID: 25154504
[TBL] [Abstract][Full Text] [Related]
2. The feasibility of in vivo detection of gadolinium by prompt gamma neutron activation analysis following gadolinium-based contrast-enhanced MRI.
Gräfe JL; McNeill FE; Byun SH; Chettle DR; Noseworthy MD
Appl Radiat Isot; 2011 Jan; 69(1):105-11. PubMed ID: 20727776
[TBL] [Abstract][Full Text] [Related]
3. A novel gadolinium-based trimetasphere metallofullerene for application as a magnetic resonance imaging contrast agent.
Adiseshaiah P; Dellinger A; MacFarland D; Stern S; Dobrovolskaia M; Ileva L; Patri AK; Bernardo M; Brooks DB; Zhou Z; McNeil S; Kepley C
Invest Radiol; 2013 Nov; 48(11):745-54. PubMed ID: 23748228
[TBL] [Abstract][Full Text] [Related]
4. A feasibility study to determine the potential of in vivo detection of gadolinium by x-ray fluorescence (XRF) following gadolinium-based contrast-enhanced MRI.
Mostafaei F; McNeill FE; Chettle DR; Noseworthy MD
Physiol Meas; 2015 Jan; 36(1):N1-13. PubMed ID: 25501799
[TBL] [Abstract][Full Text] [Related]
5. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
Liang J; Sammet S; Yang X; Jia G; Takayama Y; Knopp MV
Invest Radiol; 2010 May; 45(5):233-44. PubMed ID: 20351653
[TBL] [Abstract][Full Text] [Related]
6. Accumulation of MRI contrast agents in malignant fibrous histiocytoma for gadolinium neutron capture therapy.
Fujimoto T; Ichikawa H; Akisue T; Fujita I; Kishimoto K; Hara H; Imabori M; Kawamitsu H; Sharma P; Brown SC; Moudgil BM; Fujii M; Yamamoto T; Kurosaka M; Fukumori Y
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S355-8. PubMed ID: 19386506
[TBL] [Abstract][Full Text] [Related]
7. Incorporation of excess gadolinium into human bone from medical contrast agents.
Darrah TH; Prutsman-Pfeiffer JJ; Poreda RJ; Ellen Campbell M; Hauschka PV; Hannigan RE
Metallomics; 2009 Nov; 1(6):479-88. PubMed ID: 21305156
[TBL] [Abstract][Full Text] [Related]
8. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence.
Reimer P; Rummeny EJ; Shamsi K; Balzer T; Daldrup HE; Tombach B; Hesse T; Berns T; Peters PE
Radiology; 1996 Apr; 199(1):177-83. PubMed ID: 8633143
[TBL] [Abstract][Full Text] [Related]
9. Multicenter double-blind placebo-controlled study of gadopentetate dimeglumine as an MR contrast agent: evaluation in patients with cerebral lesions.
Russell EJ; Schaible TF; Dillon W; Drayer B; LiPuma J; Mancuso A; Maravilla K; Goldstein HA
AJR Am J Roentgenol; 1989 Apr; 152(4):813-23. PubMed ID: 2646872
[TBL] [Abstract][Full Text] [Related]
10. [Oral contrast media for magnetic resonance tomography of the abdomen. III. Initial patient research with gadolinium-DTPA].
Claussen C; Kornmesser W; Laniado M; Kaminsky S; Hamm B; Felix R
Rofo; 1988 Jun; 148(6):683-9. PubMed ID: 2837806
[TBL] [Abstract][Full Text] [Related]
11. Measurements of neutron distribution in neutrons-gamma-rays mixed field using imaging plate for neutron capture therapy.
Tanaka K; Endo S; Hoshi M
Appl Radiat Isot; 2010 Jan; 68(1):207-10. PubMed ID: 19726204
[TBL] [Abstract][Full Text] [Related]
12. Delivery of gadolinium-labeled nanoparticles to the sentinel lymph node: comparison of the sentinel node visualization and estimations of intra-nodal gadolinium concentration by the magnetic resonance imaging.
Kobayashi H; Kawamoto S; Bernardo M; Brechbiel MW; Knopp MV; Choyke PL
J Control Release; 2006 Apr; 111(3):343-51. PubMed ID: 16490277
[TBL] [Abstract][Full Text] [Related]
13. C-reactive protein levels and clinical symptoms following gadolinium administration in hemodialysis patients.
Schieren G; Tokmak F; Lefringhausen L; van Bracht M; Perings C; Willers R; Günsel A; Kemper F; Wiesmüller GA; Rump LC
Am J Kidney Dis; 2008 Jun; 51(6):976-86. PubMed ID: 18501785
[TBL] [Abstract][Full Text] [Related]
14. Gadolinium as a neutron capture therapy agent.
Shih JL; Brugger RM
Med Phys; 1992; 19(3):733-44. PubMed ID: 1508113
[TBL] [Abstract][Full Text] [Related]
15. The feasibility of in vivo quantification of bone-fluorine in humans by delayed neutron activation analysis: a pilot study.
Chamberlain M; Gräfe JL; Byun SH; Chettle DR; Egden LM; Orchard GM; Webber CE; McNeill FE
Physiol Meas; 2012 Feb; 33(2):243-57. PubMed ID: 22273740
[TBL] [Abstract][Full Text] [Related]
16. Investigating neutron activated contrast agent imaging for tumor localization in proton therapy: a feasibility study for proton neutron gamma-x detection (PNGXD).
Van Delinder KW; Crawford D; Zhang T; Khan R; Gräfe JL
Phys Med Biol; 2020 Jan; 65(3):035005. PubMed ID: 31851952
[TBL] [Abstract][Full Text] [Related]
17. An investigation of the toxicity of gadolinium based MRI contrast agents using neutron activation analysis.
Bartolini ME; Pekar J; Chettle DR; McNeill F; Scott A; Sykes J; Prato FS; Moran GR
Magn Reson Imaging; 2003 Jun; 21(5):541-4. PubMed ID: 12878264
[TBL] [Abstract][Full Text] [Related]
18. Cerebral blood volume quantification in a C6 tumor model using gadolinium per (3,6-anhydro) alpha-cyclodextrin as a new magnetic resonance imaging preclinical contrast agent.
Lahrech H; Perles-Barbacaru AT; Aous S; Le Bas JF; Debouzy JC; Gadelle A; Fries PH
J Cereb Blood Flow Metab; 2008 May; 28(5):1017-29. PubMed ID: 18183033
[TBL] [Abstract][Full Text] [Related]
19. [Oral contrast media for the magnetic resonance tomography of the abdomen. A clinical trial of the tolerance for gadolinium-DTPA].
Kaminsky S; Laniado M; Gogoll M; Kornmesser W; Clauss W; Felix R
Rofo; 1992 Jan; 156(1):17-23. PubMed ID: 1733470
[TBL] [Abstract][Full Text] [Related]
20. Detecting and measuring free gadolinium in nanoparticles for MRI imaging.
Clogston JD; Patri AK
Methods Mol Biol; 2011; 697():101-8. PubMed ID: 21116958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
